Open-Label, Randomised Parallel-Group Study

Summary

An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy.

Timeline

Start

—

Primary completion

—

Completion

—

Outcome

Outcome not reported

Stopped: “Terminated due to awaiting data from Phase II study.”

Drugs

Indications